Open AccessClinical Observation of Miglitol Combined with Insulin in Newly Diagnosed Type 2 Diabetes Mellitus
Author(s) -
Shengting Huang,
Shiying Huang
Publication year - 2021
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 2717-6096
pISSN - 2717-6088
DOI - 10.32629/jcmr.v2i3.469
Subject(s) - medicine , acarbose , postprandial , insulin glargine , diabetes mellitus , hemoglobin , type 2 diabetes mellitus , insulin , type 2 diabetes , gastroenterology , adverse effect , endocrinology
Objective — To study the clinical efficacy of miglitol combined with insulin in the treatment of newly diagnosed type 2 diabetes mellitus. Methods — 96 newly diagnosed type 2 diabetes patients admitted to our hospital from January 2021 to September 2021 were selected as the subjects of this study. They were randomly divided into two groups by drawing lots. The control group was treated with acarbose combined with insulin glargine, and the observation group was treated with miglitol combined with insulin glargine. Fasting blood glucose, 2h postprandial blood glucose, glycosylated hemoglobin (HbA1c), blood glucose compliance time, occurrence of adverse reactions and quality of life score of 2 groups were measured before and after treatment. Results — After treatment, fasting blood glucose, 2h postprandial blood glucose and HbA1c in both groups were lower than before (P 0.05). The incidence of adverse reactions in observation group was lower than that in control group, and the quality of life score in observation group was better than that in control group (P < 0.05). Conclusions — Miglitol or acarbose combined with insulin glargine can effectively control blood glucose in patients with newly diagnosed type 2 diabetes, but miglitol combined with insulin glargine has fewer adverse reactions, which can be used as the first choice for clinical treatment of newly diagnosed type 2 diabetes.